Pharmacotherapy of scleritis: Current paradigms and future directions

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: Scleritis is an inflammatory condition affecting the eye wall that may be associated with a number of systemic inflammatory diseases. Because scleritis can be refractory to standard treatment, knowledge of the body of available and emerging therapies is paramount and is reviewed here. Areas covered: This review focuses on both traditional and emerging therapies for noninfectious scleritis. The authors cover the mechanisms of action and potential adverse effects of each of the treatment modalities. In addition, a summary of the significant MEDLINE indexed literature under the subject heading 'scleritis', 'treatment', 'immunomodulator' will be provided on each therapy, including commentary on appropriate use and relative contraindications. Novel treatments and potential drug candidates that are currently being evaluated in clinical trials with therapeutic potential will also be reviewed. Expert opinion: While oral nonsteroidal anti-inflammatory drugs and oral corticosteroids are widely used, effective, first-line agents for inflammatory scleritis, refractory cases require antimetabolites, T-cell inhibitors, or biologic response modifiers. In particular, there is emerging evidence for the use of targeted biologic response modifiers, and potentially, for local drug delivery.

Original languageEnglish (US)
Pages (from-to)411-424
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number4
DOIs
StatePublished - Mar 2013

Fingerprint

Scleritis
Drug Therapy
Therapeutics
Pharmaceutical Preparations
Antimetabolites
Direction compound
Expert Testimony
Immunologic Factors
MEDLINE
Action Potentials
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Clinical Trials
T-Lymphocytes

Keywords

  • Alkylating agent
  • Antimetabolite
  • Biologic response modifier
  • Noninfectious
  • Scleritis
  • Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacotherapy of scleritis : Current paradigms and future directions. / Beardsley, Robert M.; Suhler, Eric; Rosenbaum, James (Jim); Lin, Phoebe.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 4, 03.2013, p. 411-424.

Research output: Contribution to journalArticle

@article{178a065b02c4471191226b5b7c05de3d,
title = "Pharmacotherapy of scleritis: Current paradigms and future directions",
abstract = "Introduction: Scleritis is an inflammatory condition affecting the eye wall that may be associated with a number of systemic inflammatory diseases. Because scleritis can be refractory to standard treatment, knowledge of the body of available and emerging therapies is paramount and is reviewed here. Areas covered: This review focuses on both traditional and emerging therapies for noninfectious scleritis. The authors cover the mechanisms of action and potential adverse effects of each of the treatment modalities. In addition, a summary of the significant MEDLINE indexed literature under the subject heading 'scleritis', 'treatment', 'immunomodulator' will be provided on each therapy, including commentary on appropriate use and relative contraindications. Novel treatments and potential drug candidates that are currently being evaluated in clinical trials with therapeutic potential will also be reviewed. Expert opinion: While oral nonsteroidal anti-inflammatory drugs and oral corticosteroids are widely used, effective, first-line agents for inflammatory scleritis, refractory cases require antimetabolites, T-cell inhibitors, or biologic response modifiers. In particular, there is emerging evidence for the use of targeted biologic response modifiers, and potentially, for local drug delivery.",
keywords = "Alkylating agent, Antimetabolite, Biologic response modifier, Noninfectious, Scleritis, Therapy",
author = "Beardsley, {Robert M.} and Eric Suhler and Rosenbaum, {James (Jim)} and Phoebe Lin",
year = "2013",
month = "3",
doi = "10.1517/14656566.2013.772982",
language = "English (US)",
volume = "14",
pages = "411--424",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Pharmacotherapy of scleritis

T2 - Current paradigms and future directions

AU - Beardsley, Robert M.

AU - Suhler, Eric

AU - Rosenbaum, James (Jim)

AU - Lin, Phoebe

PY - 2013/3

Y1 - 2013/3

N2 - Introduction: Scleritis is an inflammatory condition affecting the eye wall that may be associated with a number of systemic inflammatory diseases. Because scleritis can be refractory to standard treatment, knowledge of the body of available and emerging therapies is paramount and is reviewed here. Areas covered: This review focuses on both traditional and emerging therapies for noninfectious scleritis. The authors cover the mechanisms of action and potential adverse effects of each of the treatment modalities. In addition, a summary of the significant MEDLINE indexed literature under the subject heading 'scleritis', 'treatment', 'immunomodulator' will be provided on each therapy, including commentary on appropriate use and relative contraindications. Novel treatments and potential drug candidates that are currently being evaluated in clinical trials with therapeutic potential will also be reviewed. Expert opinion: While oral nonsteroidal anti-inflammatory drugs and oral corticosteroids are widely used, effective, first-line agents for inflammatory scleritis, refractory cases require antimetabolites, T-cell inhibitors, or biologic response modifiers. In particular, there is emerging evidence for the use of targeted biologic response modifiers, and potentially, for local drug delivery.

AB - Introduction: Scleritis is an inflammatory condition affecting the eye wall that may be associated with a number of systemic inflammatory diseases. Because scleritis can be refractory to standard treatment, knowledge of the body of available and emerging therapies is paramount and is reviewed here. Areas covered: This review focuses on both traditional and emerging therapies for noninfectious scleritis. The authors cover the mechanisms of action and potential adverse effects of each of the treatment modalities. In addition, a summary of the significant MEDLINE indexed literature under the subject heading 'scleritis', 'treatment', 'immunomodulator' will be provided on each therapy, including commentary on appropriate use and relative contraindications. Novel treatments and potential drug candidates that are currently being evaluated in clinical trials with therapeutic potential will also be reviewed. Expert opinion: While oral nonsteroidal anti-inflammatory drugs and oral corticosteroids are widely used, effective, first-line agents for inflammatory scleritis, refractory cases require antimetabolites, T-cell inhibitors, or biologic response modifiers. In particular, there is emerging evidence for the use of targeted biologic response modifiers, and potentially, for local drug delivery.

KW - Alkylating agent

KW - Antimetabolite

KW - Biologic response modifier

KW - Noninfectious

KW - Scleritis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84874467255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874467255&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.772982

DO - 10.1517/14656566.2013.772982

M3 - Article

C2 - 23425055

AN - SCOPUS:84874467255

VL - 14

SP - 411

EP - 424

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -